Next Article in Journal
Myeloid-Derived Suppressor Cells in Prostate Cancer: Present Knowledge and Future Perspectives
Previous Article in Journal
Capsaicin and TRPV1 Channels in the Cardiovascular System: The Role of Inflammation
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

A Novel Kinase Inhibitor AX-0085 Inhibits Interferon-γ-Mediated Induction of PD-L1 Expression and Promotes Immune Reaction to Lung Adenocarcinoma Cells

1
Department of Life Science, Ewha Womans University, Seoul 03760, Korea
2
Ewha Research Center for Systems Biology, Ewha Womans University, Seoul 03760, Korea
3
Department of Urology, College of Medicine, Hanyang University, Seoul 04763, Korea
4
R&D Center, Axceso Biopharma Co., Ltd., Yongin 14056, Korea
5
Graduate School of Biomedical Science and Engineering, Hanyang University, Seoul 04763, Korea
6
Hanyang Biomedical Research Institute, College of Medicine, Hanyang University, Seoul 04763, Korea
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Cells 2022, 11(1), 19; https://doi.org/10.3390/cells11010019
Submission received: 11 November 2021 / Revised: 14 December 2021 / Accepted: 17 December 2021 / Published: 22 December 2021
(This article belongs to the Section Cell Signaling)

Abstract

In this study, we describe a novel kinase inhibitor AX-0085 which can suppress the induction of PD-L1 expression by Interferon-γ (IFN-γ) in lung adenocarcinoma (LUAD) cells. AX-0085 effectively blocks JAK2/STAT1 signaling initiated by IFN-γ treatment and prevents nuclear localization of STAT1. Importantly, we demonstrate that AX-0085 reverses the IFN-γ-mediated repression of T cell activation in vitro and enhances the anti-tumor activity of anti-PD-1 antibody in vivo when used in combination. Finally, transcriptomic analyses indicated that AX-0085 is highly specific in targeting the IFN-γ-pathway, thereby raising the possibility of applying this reagent in combination therapy with checkpoint inhibitor antibodies. It may be particularly relevant in cases in which PD-L1-mediated T cell exhaustion leads to immunoevasive phenotypes.
Keywords: AX-0085; PD-L1; immune checkpoint; cancer immunotherapy; lung adenocarcinoma AX-0085; PD-L1; immune checkpoint; cancer immunotherapy; lung adenocarcinoma

Share and Cite

MDPI and ACS Style

Kim, J.; Jang, H.; Lee, G.J.; Hur, Y.; Keum, J.; Jo, J.K.; Yun, S.-E.; Park, S.J.; Park, Y.J.; Choi, M.J.; et al. A Novel Kinase Inhibitor AX-0085 Inhibits Interferon-γ-Mediated Induction of PD-L1 Expression and Promotes Immune Reaction to Lung Adenocarcinoma Cells. Cells 2022, 11, 19. https://doi.org/10.3390/cells11010019

AMA Style

Kim J, Jang H, Lee GJ, Hur Y, Keum J, Jo JK, Yun S-E, Park SJ, Park YJ, Choi MJ, et al. A Novel Kinase Inhibitor AX-0085 Inhibits Interferon-γ-Mediated Induction of PD-L1 Expression and Promotes Immune Reaction to Lung Adenocarcinoma Cells. Cells. 2022; 11(1):19. https://doi.org/10.3390/cells11010019

Chicago/Turabian Style

Kim, Jusong, Haeyeon Jang, Gyu Jin Lee, Yelim Hur, Juhee Keum, Jung Ki Jo, Si-Eun Yun, Sung Jun Park, Young Jun Park, Myeong Jun Choi, and et al. 2022. "A Novel Kinase Inhibitor AX-0085 Inhibits Interferon-γ-Mediated Induction of PD-L1 Expression and Promotes Immune Reaction to Lung Adenocarcinoma Cells" Cells 11, no. 1: 19. https://doi.org/10.3390/cells11010019

APA Style

Kim, J., Jang, H., Lee, G. J., Hur, Y., Keum, J., Jo, J. K., Yun, S.-E., Park, S. J., Park, Y. J., Choi, M. J., Kim, K.-S., & Kim, J. (2022). A Novel Kinase Inhibitor AX-0085 Inhibits Interferon-γ-Mediated Induction of PD-L1 Expression and Promotes Immune Reaction to Lung Adenocarcinoma Cells. Cells, 11(1), 19. https://doi.org/10.3390/cells11010019

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop